Stemline Therapeutics, Inc. (NASDAQ:STML) has been given an average recommendation of “Buy” by the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $32.25.

Several equities analysts have recently commented on STML shares. Wedbush boosted their price objective on Stemline Therapeutics from $33.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, May 11th. Cowen and Company restated a “buy” rating on shares of Stemline Therapeutics in a research report on Thursday, March 23rd. Ladenburg Thalmann Financial Services set a $41.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a research report on Monday, March 20th. Jefferies Group LLC restated a “buy” rating and issued a $16.00 price objective on shares of Stemline Therapeutics in a research report on Thursday, May 25th. Finally, HC Wainwright restated a “buy” rating and issued a $34.00 price objective on shares of Stemline Therapeutics in a research report on Tuesday, March 28th.

Several large investors have recently bought and sold shares of STML. Wells Fargo & Company MN increased its stake in Stemline Therapeutics by 3.8% in the first quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 500 shares in the last quarter. Nationwide Fund Advisors increased its stake in Stemline Therapeutics by 7.8% in the first quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 858 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Stemline Therapeutics by 8.7% in the first quarter. Ameriprise Financial Inc. now owns 43,900 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 3,500 shares in the last quarter. Renaissance Technologies LLC increased its stake in Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 4,800 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its stake in Stemline Therapeutics by 14.5% in the first quarter. TIAA CREF Investment Management LLC now owns 62,199 shares of the biopharmaceutical company’s stock worth $532,000 after buying an additional 7,888 shares in the last quarter. Institutional investors own 54.18% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/04/stemline-therapeutics-inc-nasdaqstml-given-consensus-rating-of-buy-by-analysts.html.

Shares of Stemline Therapeutics (STML) opened at 9.25 on Tuesday. Stemline Therapeutics has a 12-month low of $5.50 and a 12-month high of $14.60. The firm has a 50 day moving average price of $8.23 and a 200 day moving average price of $8.98. The stock’s market cap is $216.23 million.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.22. Stemline Therapeutics had a negative net margin of 3,864.20% and a negative return on equity of 60.51%. The business had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.30 million. On average, equities analysts expect that Stemline Therapeutics will post ($2.27) EPS for the current year.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.